I understand the commercial benefits of approvals for Back pain and heart failure, the same commercial benefits were thrown around for Covid 2 years ago. Gvhd irrelevant?? Its the only product that MSB draws revenue from.
can anyone deny this........... If it was successful in Japan we would have seen a statement from Si or the company to this effect.......
"Our product halves the mortality rate in Japan for GVHD and we are looking forward to approvals in more jurisdictions to help many more people around the world"
someone please reduce the smelliness for me on the above
Growing doubt on COVID-19 Application, page-3334
-
- There are more pages in this discussion • 1,401 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.000(0.00%) |
Mkt cap ! $1.672B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 680 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 188 | 1 |
View Market Depth
| Last trade - 09.44am 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable